Previous studies have successfully utilized CRISPR/Cas9 technology to establish knockout models of B2M, JAK1, and LMP2 in the mouse EMT6 breast cancer cell line, as well as B2M knockout clone model in the mouse MC38 colon cancer cell line. This evidence concerns the gene B2M and colonic neoplasm.